Laddar...
Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis
With 12 available US Food and Drug Administration approved medications for the treatment of relapsing multiple sclerosis (MS), choosing an initial therapy is no longer a straightforward task. Each disease-modifying therapy (DMT) has a distinct risk–benefit profile and each patient is an individual....
Sparad:
| I publikationen: | Ther Adv Neurol Disord |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
SAGE Publications
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622114/ https://ncbi.nlm.nih.gov/pubmed/26557897 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285615598910 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|